- Market Capitalization, $K 22,904,756
- Shares Outstanding, K 654,983
- Annual Sales, $ 804,360 K
- Annual Income, $ 324,680 K
- 60-Month Beta 0.85
- Price/Sales 28.47
- Price/Cash Flow 65.84
- Price/Book 8.66
|Period||Period Low||Period High||Performance|
| || |
-3.17 (-8.58%)since 09/28/20
| || |
-1.48 (-4.20%)since 07/28/20
| || |
+12.46 (+58.44%)since 10/28/19
Aging population, lifestyle changes and pandemics have created a huge demand for patient-focused healthcare. Biotech stocks like Seagen (SGEN), Genmab A/S (GMAB), Amedisys (AMED), and Masimo (MASI) could...
With huge investments being made in biotech thanks to the pandemic, there has been a renewed focus on biotech stocks. Here are four worth considering: Amgen (AMGN), Immunomedics (IMMU), Seattle Genetics...
Amgen (AMGN), Genmab A/S (GMAB), Seattle Genetics (SGEN), and Alexion Pharmaceuticals (ALXN) are leading biotech companies engaged in developing cancer drugs. As the number of cancer patients rises with...
Moderna (MRNA) is one of the leading biotech manufacturers in the race to develop a coronavirus vaccine. The stock seems overvalued by traditional measures, but the company’s unique approach to developing...
--- Biologics License Application Submission Planned to Support Accelerated Approval Pathway with the FDA -
Healthcare players such as Regeneron Pharmaceuticals (REGN), Genmab (GMAB), Horizon Therapeutics (HZNP), and Bio-Rad Laboratories (BIO) demonstrated high-profit margins and are expected to witness a surge...
Seattle Genetics (SGEN) to win a milestone fee from GlaxoSmithKline following the EU approval of Blenrep, developed by the latter. Blenrep is made using the company's proprietary technology.
AbbVie's (ABBV) key drug, Humira is seeing strong demand in the United States while generics are eroding ex-U.S. sales. New drugs Skyrizi and Rinvoq are seeing strong sales uptake.
Genmab's (GMAB) second-quarter revenues are likely to have been driven by royalties on sales of J&J's Darzalex. Several pipeline candidates are under development.
Genmab AS Sponsored ADR (GMAB) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.
|Advisorshares Dorsey Wright ETF|
|GS Activebeta Europe Equity ETF|
|Nasdaq Biotechnology Ishares ETF|
|GS Activebeta International ETF|
|ACWI Low Carbon Target Ishares MSCI ETF|